Oncothyreon and Celldex Therapeutics Announce Collaboration for Combination Immunotherapy Clinical Trial of ONT-10 and Varlilumab

May 29, 2014 Oncothyreon Inc. and Celldex Therapeutics, Inc., today announced that they have agreed to collaborate on a combined clinical trial of ONT-10 and varlilumab. ONT-10 is a therapeutic vaccine targeting the tumor-associated antigen MUC1. Varlilumab is a fully human monoclonal antibody that targets CD27, a critical molecule in the activation pathway of lymphocytes. The planned trial is an …

EMD Serono Announces Initiation of Phase III START2 Study with Tecemotide in Stage III Non-Small Cell Lung Cancer

First patient dosed in tecemotide Phase III trial; study recruiting across 250 sites in over 20 countries START2 builds upon the data from the START* trial and explores the potential of tecemotide in patients with Stage III NSCLC who have demonstrated stable disease or objective response after concurrent chemoradiotherapy April 7, 2014 EMD Serono, Inc., a subsidiary of Merck KGaA, …

Prima BioMed’s CVac Data Demonstrating Improvement in PFS in Second Remission Ovarian Cancer Accepted for Oral Presentation at ASCO

March 28, 2014 Prima BioMed LtdĀ announced today that the American Society of Clinical Oncology has accepted the abstract entitled, “Progression-free survival in ovarian cancer patients in second remission is improved with mucin-1 autologous dendritic cell therapy” for oral presentation at the Gynecologic Cancer Session at the 2014 ASCO Annual Meeting to be held May 30 – June 3, 2014 in …